Abstract
The majority of drugs approved by the United States Food and Drug Administration (FDA) are not labeled for use in pediatric patients. Infants and young children may often benefit from such medicines; however, lack of an appropriate formulation is a ratelimiting step for clinical use or for conducting important research to develop optimal dosage guidelines. Stability studies on extemporaneous formulations must be performed to assure the delivery of desired doses. The data on bioavailability, efficacy, and safety of these formulations should also be collected, when possible. The funding of research on extemporaneous formulations should be increased. The FDA and the National Institute of Child Health and Human Development (through its Pediatric Pharmacology Research Units) should work with academia and industry to develop pediatric drug formulations and seek labeling for their use.
Similar content being viewed by others
References
NIH News Alert. National Institute of Child Health and Human Development. National Institutes of Health, Bethesda, MD. November 25, 1997.
Nahata MC, Hippie TF. Pediatric Drug Formulations. 3rd edition. Cincinnati, OH: Harvey Whitney Books Co.; 1997;1–118.
Nahata MC. Pediatrics. In: Pharmacotherapy. DiPiro J, Talbert R, Yee G, Matzke G, Wells B, Posey M (eds.), 3rd ed. Stanford, CT: Appleton & Lange; 1997; 77–86.
Nahata MC, Morosco RS, Hippie TF. Stability of captopril in liquid containing ascorbic acid or sodium ascorbate. Am J Hosp Pharm. 1994;51:1707–1708.
Trissel LA. Assay reliability. Am J Health Syst Pharm. 1998;55:491 (letter).
ASHP Reports. Council on Professional Affairs. Am J Health Syst Pharm. 1997;54:819–826.
US Department of Health and Human Services. Food and Drug Administration. 21CFR Parts 201,312, 314, and 601. [Docket No. 97N-0165]. RIN 0910-AB20. Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drugs and Biological Products in Pediatric Patients. August 17, 1997.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nahata, M.C. Pediatric Drug Formulations: A Rate-Limiting Step. Ther Innov Regul Sci 33, 393–396 (1999). https://doi.org/10.1177/009286159903300210
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286159903300210